About Beta-1,3-N-acetylglucosaminyltransferase manic fringe
Beta-1,3-N-acetylglucosaminyltransferase manic fringe (MFNG) is a protein
from Homo sapiens identified by UniProt accession
O00587, 321 residues long.
MolForge cross-references it against 0 known binders and
80 disease associations.
Target properties
| Protein name | Beta-1,3-N-acetylglucosaminyltransferase manic fringe |
| UniProt accession | O00587 |
| Gene | MFNG |
| Organism | Homo sapiens |
| Length | 321 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (80)
Diseases linked to this target (Open Targets).
- glioblastoma multiforme · score 0.21
- squamous cell lung carcinoma · score 0.18
- gastric adenocarcinoma · score 0.11
- esophageal cancer · score 0.11
- blood protein measurement · score 0.08
- triple-negative breast cancer · score 0.07
- isolated agammaglobulinemia · score 0.04
- common variable immunodeficiency · score 0.04
- severe combined immunodeficiency due to CTPS1 deficiency · score 0.04
- immunodeficiency 18 · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O00587-F1 | alphafold | PREDICTED | 90.22 | — |
Amino-acid sequence (321 residues)
MQCRLPRGLA GALLTLLCMG LLCLRYHLNL SPQRVQGTPE LSQPNPGPPK LQLHDVFIAV KTTRAFHRLR LELLLDTWVS RTREQTFVFT DSPDKGLQER LGSHLVVTNC SAEHSHPALS CKMAAEFDTF LASGLRWFCH VDDDNYVNPR ALLQLLRAFP LARDVYVGRP SLNRPIHASE PQPHNRTRLV QFWFATGGAG FCINRKLALK MAPWASGSRF MDTSALIRLP DDCTMGYIIE CKLGGRLQPS PLFHSHLETL QLLRTAQLPE QVTLSYGVFE GKLNVIKLQG PFSPEEDPSR FRSLHCLLYP DTPWCPQLGA R
Explore Beta-1,3-N-acetylglucosaminyltransferase manic fringe with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets